About Immunotherapy

Leveraging the patient's own immune system, modern technologies enable the collection and ex vivo expansion of different immune cell types, which are then infused back into the patient. Often, these immune cells are genetically modified to enhance their activity. Examples of this therapeutic modality include CAR-T, CAR-NK, TCR-T or TILs.

Using monoclonal antibodies or small molecules, it is possible to block the interaction between an immune checkpoint present in immune cells and its inhibitory receptor, unleashing a latent immune response against the tumor.

Utilizing small molecules, haptens or antibodies it is possible to modulate the immune system in many different ways to mount an effective anti-tumor response by stimulating innate and/or adaptive immune responses.

Utilizing sophisticated prediction algorithms and different vaccination technologies, it is possible to identify genes that are tumor specific and use them to train the immune system to identify and destroy immune cells.

Leveraging the innate tropism of some virus for tumor cells, it is possible to engineer novel virus that can specifically target and destroy tumor cells, often in collaboration with the immune system.

Using monoclonal or bispecific antibodies it is possible to retarget immune cells into attacking tumor cells or switch inhibitory signals into stimulatory ones, improving or enabling an effective anti-tumor response.